CytomX Therapeutics (CTMX) Interest & Investment Income (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Interest & Investment Income data on file, last reported at $1.5 million in Q1 2026.

• Quarterly Interest & Investment Income rose 56.02% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (down 2.65% YoY) and the FY2025 annual result came in at $5.2 million, down 27.05% from the prior year.
• Interest & Investment Income improved to $1.5 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $2.7 million in Q3 2023 to a low of $68000.0 in Q1 2022.
• A 5-year average of $1.5 million and a median of $1.5 million in 2026 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2023 — Interest & Investment Income surged 3322.06% — and 2025, when it tumbled 56.47%.
• Tracing CTMX's Interest & Investment Income over 5 years: stood at $732000.0 in 2022, then jumped by 241.94% to $2.5 million in 2023, then sank by 48.94% to $1.3 million in 2024, then climbed by 15.88% to $1.5 million in 2025, then advanced by 0.61% to $1.5 million in 2026.
• The last three Interest & Investment Income figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.